Imagyn Medical Inc.: Building a Market Franchise in Women's Health
Executive Summary
Imagyn faces problems common to small device companies: a daunting FDA, less lucrative end-markets, and lack of effective distribution. Short-term it’s betting on US Surgical to market its products. Longer-term it hopes to grow by building a portfolio of products that move gynecological and infertility procedures out of the hospital.
You may also be interested in...
Industry Impact: Siemens Healthineers $16.4BN Acquisition Of Varian – What Next?
Siemens Healthineers' acquisition of radiation oncology company Varian Medical Systems creates an oncology giant. Analysts disagree on whether its the right move for the companies.
Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Teva Sees COVID Sales Correction
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.
Need a specific report? 1000+ reports available
Buy Reports